CTVA vs PRME
CTVA: A leading agricultural company developing and commercializing seeds, crop protection chemicals, and agronomic solutions to improve crop yields and farm productivity globally. PRME: A biotechnology company developing next-generation gene editing therapies based on its proprietary Prime Editing platform to cure serious genetic diseases.
Side-by-side fundamentals
| Metric | CTVA | PRME | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $88.53 | $3.09 | |
| Market cap as of 2026-07-23 | $59.0B | $564M | |
| P/E as of 2026-07-23 | 50.81 | n/a | |
| PEG as of 2026-07-23 | 3.98 | n/a | |
| Net margin as of 2026-07-23 | +6.5% | -4917.6% | CTVA higher |
| Gross margin as of 2026-07-23 | +48.6% | n/a | |
| Operating margin as of 2026-07-23 | +15.0% | -5121.8% | CTVA higher |
| ROE as of 2026-07-23 | +4.7% | -188.8% | CTVA higher |
| ROA as of 2026-07-23 | +2.7% | -61.0% | CTVA higher |
| Debt / equity as of 2026-07-23 | 0.14 | 0.00 | PRME lower |
| Revenue growth (YoY) as of 2026-07-23 | +6.3% | +4.9% | CTVA higher |
| Revenue CAGR (3y) SEC XBRL | -0.1% | n/a | |
| Dividend yield as of 2026-07-23 | +0.8% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-07-23 | 0.57 | 2.27 | |
| 1-year return as of 2026-07-22 close | +20.0% | -31.7% | CTVA higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.